{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T20:58:27Z","timestamp":1789160307001,"version":"build-2803163510"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2024,12,16]],"date-time":"2024-12-16T00:00:00Z","timestamp":1734307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,12,16]],"date-time":"2024-12-16T00:00:00Z","timestamp":1734307200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100014759","name":"Medical Scientific Research Foundation of Zhejiang Province, China","doi-asserted-by":"publisher","award":["2022RC223"],"award-info":[{"award-number":["2022RC223"]}],"id":[{"id":"10.13039\/501100014759","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Medical Health Science and Technology Project of Zhejiang Provincial Health Commission","award":["2021KY574"],"award-info":[{"award-number":["2021KY574"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Gynecol Obstet"],"DOI":"10.1007\/s00404-024-07863-x","type":"journal-article","created":{"date-parts":[[2024,12,16]],"date-time":"2024-12-16T13:02:32Z","timestamp":1734354152000},"page":"405-414","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Secondary cytoreductive surgery in platinum-sensitive relapsed ovarian cancer: a meta-analysis of randomized controlled trials"],"prefix":"10.1007","volume":"311","author":[{"given":"Qingqing","family":"Lin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenchao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanglong","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3173-6390","authenticated-orcid":false,"given":"Xinyu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,16]]},"reference":[{"key":"7863_CR1","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3322\/caac.21820","volume":"74","author":"RL Siegel","year":"2024","unstructured":"Siegel RL, Giaquinto AN, Jemal A (2024) Cancer statistics, 2024. CA Cancer J Clin 74:12\u201349","journal-title":"CA Cancer J Clin"},{"key":"7863_CR2","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1001\/jamaoncol.2018.2761","volume":"4","author":"RL Dood","year":"2018","unstructured":"Dood RL, Zhao Y, Armbruster SD, Coleman RL, Tworoger S et al (2018) Defining survivorship trajectories across patients with solid tumors: an evidence-based approach. JAMA Oncol 4:1519\u20131526","journal-title":"JAMA Oncol"},{"key":"7863_CR3","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1016\/j.ygyno.2022.03.024","volume":"165","author":"N Bizzarri","year":"2022","unstructured":"Bizzarri N, Marchetti C, Conte C, Loverro M, Giudice MT et al (2022) The impact of secondary cytoreductive surgery in platinum sensitive recurrent ovarian cancer treated with upfront neoadjuvant chemotherapy and interval debulking surgery. Gynecol Oncol 165:453\u2013458","journal-title":"Gynecol Oncol"},{"key":"7863_CR4","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1016\/S1470-2045(17)30279-6","volume":"18","author":"RL Coleman","year":"2017","unstructured":"Coleman RL, Brady MF, Herzog TJ, Sabbatini P, Armstrong DK et al (2017) Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology\/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol 18:779\u2013791","journal-title":"Lancet Oncol"},{"key":"7863_CR5","doi-asserted-by":"publisher","first-page":"191","DOI":"10.6004\/jnccn.2021.0007","volume":"19","author":"DK Armstrong","year":"2021","unstructured":"Armstrong DK, Alvarez RD, Bakkum-Gamez JN, Barroilhet L, Behbakht K et al (2021) Ovarian cancer, version 2.2020, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw 19:191\u2013226","journal-title":"J Natl Compr Canc Netw"},{"issue":"Suppl 1","key":"7863_CR6","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1002\/ijgo.13878","volume":"155","author":"JS Berek","year":"2021","unstructured":"Berek JS, Renz M, Kehoe S, Kumar L, Friedlander M (2021) Cancer of the ovary, fallopian tube, and peritoneum: 2021 update. Int J Gynaecol Obstet 155(Suppl 1):61\u201385","journal-title":"Int J Gynaecol Obstet"},{"key":"7863_CR7","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1016\/S1470-2045(21)00073-5","volume":"22","author":"A Poveda","year":"2021","unstructured":"Poveda A, Floquet A, Ledermann JA, Asher R, Penson RT et al (2021) Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1\/2 mutation (SOLO2\/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol 22:620\u2013631","journal-title":"Lancet Oncol"},{"key":"7863_CR8","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1245\/s10434-011-1873-2","volume":"19","author":"WJ Tian","year":"2012","unstructured":"Tian WJ, Chi DS, Sehouli J, Trope CG, Jiang R et al (2012) A risk model for secondary cytoreductive surgery in recurrent ovarian cancer: an evidence-based proposal for patient selection. Ann Surg Oncol 19:597\u2013604","journal-title":"Ann Surg Oncol"},{"key":"7863_CR9","first-page":"CD008765","volume":"2013","author":"T Al Rawahi","year":"2013","unstructured":"Al Rawahi T, Lopes AD, Bristow RE, Bryant A, Elattar A et al (2013) Surgical cytoreduction for recurrent epithelial ovarian cancer. Cochrane Database Syst Rev 2013:CD008765","journal-title":"Cochrane Database Syst Rev"},{"key":"7863_CR10","doi-asserted-by":"publisher","first-page":"510","DOI":"10.21037\/atm-20-4690","volume":"9","author":"C Conte","year":"2021","unstructured":"Conte C, Fagotti A, Avesani G, Trombadori C, Federico A et al (2021) Update on the secondary cytoreduction in platinum-sensitive recurrent ovarian cancer: a narrative review. Ann Transl Med 9:510","journal-title":"Ann Transl Med"},{"key":"7863_CR11","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1186\/s13048-021-00842-9","volume":"14","author":"T Ding","year":"2021","unstructured":"Ding T, Tang D, Xi M (2021) The survival outcome and complication of secondary cytoreductive surgery plus chemotherapy in recurrent ovarian cancer: a systematic review and meta-analysis. J Ovarian Res 14:93","journal-title":"J Ovarian Res"},{"key":"7863_CR12","doi-asserted-by":"publisher","first-page":"1292","DOI":"10.1016\/j.medj.2021.11.001","volume":"2","author":"JCM Wan","year":"2021","unstructured":"Wan JCM, Mughal TI, Razavi P, Dawson SJ, Moss EL et al (2021) Liquid biopsies for residual disease and recurrence. Med 2:1292\u20131313","journal-title":"Med"},{"key":"7863_CR13","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/1471-2407-14-22","volume":"14","author":"R van de Laar","year":"2014","unstructured":"van de Laar R, Zusterzeel PL, Van Gorp T, Buist MR, van Driel WJ et al (2014) Cytoreductive surgery followed by chemotherapy versus chemotherapy alone for recurrent platinum-sensitive epithelial ovarian cancer (SOCceR trial): a multicenter randomised controlled study. BMC Cancer 14:22","journal-title":"BMC Cancer"},{"key":"7863_CR14","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1097\/IGC.0000000000000841","volume":"27","author":"R van de Laar","year":"2017","unstructured":"van de Laar R, Kruitwagen RF, Zusterzeel PL, Van Gorp T, Massuger LF (2017) Correspondence: premature stop of the SOCceR trial, a multicenter randomized controlled trial on secondary cytoreductive surgery: Netherlands trial register number: NTR3337. Int J Gynecol Cancer 27:2","journal-title":"Int J Gynecol Cancer"},{"key":"7863_CR15","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1056\/NEJMoa1902626","volume":"381","author":"RL Coleman","year":"2019","unstructured":"Coleman RL, Spirtos NM, Enserro D, Herzog TJ, Sabbatini P et al (2019) Secondary surgical cytoreduction for recurrent ovarian cancer. N Engl J Med 381:1929\u20131939","journal-title":"N Engl J Med"},{"key":"7863_CR16","first-page":"332","volume":"18","author":"D Margul","year":"2020","unstructured":"Margul D, Coleman RL, Herzog TJ (2020) The current status of secondary cytoreduction in ovarian cancer: a systematic review. Clin Adv Hematol Oncol 18:332\u2013343","journal-title":"Clin Adv Hematol Oncol"},{"key":"7863_CR17","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1056\/NEJMoa2103294","volume":"385","author":"P Harter","year":"2021","unstructured":"Harter P, Sehouli J, Vergote I, Ferron G, Reuss A et al (2021) Randomized trial of cytoreductive surgery for relapsed ovarian cancer. N Engl J Med 385:2123\u20132131","journal-title":"N Engl J Med"},{"key":"7863_CR18","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/S1470-2045(21)00006-1","volume":"22","author":"T Shi","year":"2021","unstructured":"Shi T, Zhu J, Feng Y, Tu D, Zhang Y et al (2021) Secondary cytoreduction followed by chemotherapy versus chemotherapy alone in platinum-sensitive relapsed ovarian cancer (SOC-1): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol 22:439\u2013449","journal-title":"Lancet Oncol"},{"key":"7863_CR19","doi-asserted-by":"publisher","first-page":"2181","DOI":"10.1038\/s41591-024-02981-0","volume":"30","author":"R Jiang","year":"2024","unstructured":"Jiang R, Feng Y, Chen Y, Cheng X, Shi T et al (2024) Surgery versus no surgery in platinum-sensitive relapsed ovarian cancer: final overall survival analysis of the SOC-1 randomized phase 3 trial. Nat Med 30:2181\u20132188","journal-title":"Nat Med"},{"key":"7863_CR20","doi-asserted-by":"publisher","first-page":"3258","DOI":"10.1245\/s10434-020-09226-7","volume":"28","author":"C Marchetti","year":"2021","unstructured":"Marchetti C, Fagotti A, Tombolini V, Scambia G, De Felice F (2021) The role of secondary cytoreductive surgery in recurrent ovarian cancer: a systematic review and meta-analysis. ann Surg Oncol 28:3258\u20133263","journal-title":"ann Surg Oncol"},{"key":"7863_CR21","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.1200\/JCO.21.02085","volume":"40","author":"MH Baek","year":"2022","unstructured":"Baek MH, Park EY, Ha HI, Park SY, Lim MC et al (2022) Secondary cytoreductive surgery in platinum-sensitive recurrent ovarian cancer: a meta-analysis. J Clin Oncol 40:1659\u20131670","journal-title":"J Clin Oncol"},{"key":"7863_CR22","doi-asserted-by":"publisher","first-page":"3470","DOI":"10.3390\/cancers15133470","volume":"15","author":"MT Climent","year":"2023","unstructured":"Climent MT, Serra A, Llueca M, Llueca A (2023) Surgery in recurrent ovarian cancer: a meta-analysis. Cancers (Basel) 15:3470","journal-title":"Cancers (Basel)"},{"key":"7863_CR23","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1136\/ijgc-2023-004342","volume":"33","author":"S Gulia","year":"2023","unstructured":"Gulia S, Kannan S, Ghosh J, Rath S, Maheshwari A et al (2023) Secondary cytoreduction in platinum sensitive relapsed ovarian cancer: an individual patient level meta-analysis. Int J Gynecol Cancer 33:1440\u20131447","journal-title":"Int J Gynecol Cancer"},{"key":"7863_CR24","doi-asserted-by":"publisher","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","volume":"6","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG, Group P (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 6:e1000097","journal-title":"PLoS Med"},{"key":"7863_CR25","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.d5928","volume":"343","author":"JP Higgins","year":"2011","unstructured":"Higgins JP, Altman DG, Gotzsche PC, Juni P, Moher D et al (2011) The cochrane collaboration\u2019s tool for assessing risk of bias in randomised trials. BMJ 343:d5928","journal-title":"BMJ"},{"key":"7863_CR26","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1097\/XEB.0000000000000065","volume":"13","author":"C Tufanaru","year":"2015","unstructured":"Tufanaru C, Munn Z, Stephenson M, Aromataris E (2015) Fixed or random effects meta-analysis? Common methodological issues in systematic reviews of effectiveness. Int J Evid Based Healthc 13:196\u2013207","journal-title":"Int J Evid Based Healthc"},{"key":"7863_CR27","doi-asserted-by":"publisher","DOI":"10.3802\/jgo.2021.32.e19","volume":"32","author":"E Sarah","year":"2021","unstructured":"Sarah E, Oliver Z, Dennis SC (2021) Why was GOG-0213 a negative trial? J Gynecol Oncol 32:e19","journal-title":"J Gynecol Oncol"},{"key":"7863_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/GCO.0000000000000831","volume":"35","author":"D Krause","year":"2023","unstructured":"Krause D, Richardson DL (2023) Is there a role for secondary debulking in ovarian cancer? A review of the current literature. Curr Opin Obstet Gynecol 35:1\u20135","journal-title":"Curr Opin Obstet Gynecol"},{"key":"7863_CR29","doi-asserted-by":"publisher","first-page":"1029976","DOI":"10.3389\/fonc.2022.1029976","volume":"12","author":"E de Bree","year":"2022","unstructured":"de Bree E, Michelakis D, Anagnostopoulou E (2022) The current role of secondary cytoreductive surgery for recurrent ovarian cancer. Front Oncol 12:1029976","journal-title":"Front Oncol"},{"key":"7863_CR30","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1016\/j.ygyno.2021.10.008","volume":"163","author":"R Harrison","year":"2021","unstructured":"Harrison R, Zighelboim I, Cloven NG, Marcus JZ, Coleman RL et al (2021) Secondary cytoreductive surgery for recurrent ovarian cancer: an SGO clinical practice statement. Gynecol Oncol 163:448\u2013452","journal-title":"Gynecol Oncol"},{"key":"7863_CR31","first-page":"1727","volume":"63","author":"JH Goldie","year":"1979","unstructured":"Goldie JH, Coldman AJ (1979) A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treat Rep 63:1727\u20131733","journal-title":"Cancer Treat Rep"},{"key":"7863_CR32","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/j.ygyno.2014.01.027","volume":"132","author":"P Harter","year":"2014","unstructured":"Harter P, Beutel B, Alesina PF, Lorenz D, Boergers A et al (2014) Prognostic and predictive value of the arbeitsgemeinschaft gynaekologische onkologie (AGO) score in surgery for recurrent ovarian cancer. Gynecol Oncol 132:537\u2013541","journal-title":"Gynecol Oncol"},{"key":"7863_CR33","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.ygyno.2016.01.027","volume":"141","author":"JM Janco","year":"2016","unstructured":"Janco JM, Kumar A, Weaver AL, McGree ME, Cliby WA (2016) Performance of AGO score for secondary cytoreduction in a high-volume U.S. center. Gynecol Oncol 141:140\u2013147","journal-title":"Gynecol Oncol"},{"key":"7863_CR34","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/j.ygyno.2017.02.010","volume":"145","author":"RA Cowan","year":"2017","unstructured":"Cowan RA, Eriksson AGZ, Jaber SM, Zhou Q, Iasonos A et al (2017) A comparative analysis of prediction models for complete gross resection in secondary cytoreductive surgery for ovarian cancer. Gynecol Oncol 145:230\u2013235","journal-title":"Gynecol Oncol"},{"key":"7863_CR35","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1097\/IGC.0000000000001219","volume":"28","author":"T Laga","year":"2018","unstructured":"Laga T, Lambrechts S, Laenen A, Van Nieuwenhuysen E, Han SN et al (2018) Positive DESKTOP and Tian Scores Systems Are Adequate to Predict Optimal (R0) Secondary Debulking Surgery in Ovarian Cancer, But a Negative Score Does Not Preclude Secondary Surgery. Int J Gynecol Cancer 28:721\u2013728","journal-title":"Int J Gynecol Cancer"},{"key":"7863_CR36","doi-asserted-by":"publisher","DOI":"10.3802\/jgo.2019.30.e100","volume":"30","author":"M So","year":"2019","unstructured":"So M, Miyamoto T, Murakami R, Abiko K, Hamanishi J et al (2019) The efficacy of secondary cytoreductive surgery for recurrent ovarian, tubal, or peritoneal cancer in Tian-model low-risk patients. J Gynecol Oncol 30:e100","journal-title":"J Gynecol Oncol"},{"key":"7863_CR37","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.674637","volume":"11","author":"C Jiang","year":"2021","unstructured":"Jiang C, Li Z (2021) Prediction models for complete resection in secondary cytoreductive surgery of patients with recurrent ovarian cancer. Front Oncol 11:674637","journal-title":"Front Oncol"},{"key":"7863_CR38","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1097\/AOG.0000000000002796","volume":"132","author":"ND Fleming","year":"2018","unstructured":"Fleming ND, Nick AM, Coleman RL, Westin SN, Ramirez PT et al (2018) Laparoscopic surgical algorithm to triage the timing of tumor reductive surgery in advanced ovarian cancer. Obstet Gynecol 132:545\u2013554","journal-title":"Obstet Gynecol"}],"container-title":["Archives of Gynecology and Obstetrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00404-024-07863-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00404-024-07863-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00404-024-07863-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,8]],"date-time":"2025-03-08T11:10:45Z","timestamp":1741432245000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00404-024-07863-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,16]]},"references-count":38,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,2]]}},"alternative-id":["7863"],"URL":"https:\/\/doi.org\/10.1007\/s00404-024-07863-x","relation":{},"ISSN":["1432-0711"],"issn-type":[{"value":"1432-0711","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,16]]},"assertion":[{"value":"1 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"Not required.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}